Objective: The objective of this study is to determine the breadth of HIV-1 Env-specific antibody-dependent cellular cytotoxicity (ADCC) in HIV controllers and HIV progressors with a view to design globally relevant HIV vaccines.
Introduction
Combination antiretroviral treatment (cART) has greatly improved the health of HIV-infected individuals [1] . Nevertheless, a vaccine for HIV remains a global health priority to contain the HIV pandemic. Although human vaccine trials based on the induction of neutralizing antibodies (NAbs) and cytotoxic T-lymphocyte (CTL) responses have failed to afford protection [2] [3] [4] , the partial efficacy of the RV144 trial (31% protection; P ¼ 0.04) sparked a large posthoc analysis in which HIV-specific antibody-dependent cellular cytotoxicity (ADCC) has emerged as a possible correlate of protection [5] [6] [7] [8] .
Some individuals control HIV progression without ART for many years. Such individuals (broadly called 'HIV controllers') have been variously termed long-term slow progressors (LTSP; often defined clinically as maintaining CD4 þ T-cell count >400 cells/ml more than 7 years after acquisition of HIV), viremic controllers (who maintain plasma viral loads <3000 copies/ml for at least 1 year) elite controllers (maintain undetectable virus in the plasma for at least 1 year) [9] and posttreatment controllers (PTCs: maintain undetectable viremia after an initial period of cART) [10] . HIV-infected individuals who progress in a typical time frame usually have viral loads of more than 10 000 copies/ml [11] . Although viral factors (such as nefdeleted viral mutations) may play a role in facilitating slow progression in some cases [12] , host factors are thought to primarily contribute to containment of HIV infection in HIV controllers [13] . For example, potentially protective CTL responses preferentially targeting Gag have been noted in elite controller and viremic controller individuals [13, 14] . HLA-B27 and HLA-B57 alleles are overrepresented in HIV controllers and their interaction with natural killer (NK) cells and killer immunoglobulin-like receptors (KIR) have been associated with slow progression to AIDS [13] [14] [15] . Although HIV-1 envelope protein (Env) has generally been considered an ideal target for a vaccine, Env-specific CTL responses and NAb levels have generally been found to be lower in elite controllers [14, [16] [17] [18] . On the contrary, anti-HIV ADCC responses have been associated with slower immunodeficiency virus disease progression in humans and macaques in most studies [17, [19] [20] [21] [22] [23] . Whether such ADCC responses can target a diverse range of Env strains, however, is largely unknown. Given the interest in ADCC-based HIV vaccines following the RV144 trial, it is important to define the breadth of ADCC immunity that facilitate control of HIV.
The diversity of HIV is a major problem for HIV vaccine design [24, 25] . HIV-1 is catogorized into four groups: M (main), O (outlier), N (non-M, non-O) and the recently recognised P. The M group, which accounts for the vast majority of HIV infections, contains nine subtypes (A through J), approximately 58 circulating recombinant forms (CRFs) and multiple unique recombinant forms (URFs) [26] . In 2004-2007, global HIV infections were caused by subtype A (12% of infections), subtype B (11%), subtype C (48%), CRF01_AE (5%) and subtype D (2%) [27] . Genetic variation between subtypes is 25-35% and genetic variation within subtypes is 15-20% [26] . Immune responses capable of contending with the high genetic diversity of HIV are imperative in efforts to develop a globally relevant HIV vaccine. Glycosylation adds another level of complexity to HIV-1 Env and it may be beneficial if Env-specific immune responses recognize diverse glycosylation profiles. Protein glycosylation is often considered a hindrance to effective NAb responses, with the glycan moieties masking critical neutralization sites [28] . However, some more recently described broadly NAbs (bNAbs) specifically target epitopes that include conserved glycan moieties [29, 30] . Another concern with NAb responses to Env is that responses directed against gp140 trimers are thought to be more efficacious than responses directed against gp120 [31] . However, ADCC responses directed against epitopes on the nonexposed surfaces of gp120 may be useful, as such epitopes may be expressed on the surface of HIV-infected cells [32] . The magnitude and breadth of ADCC responses to both gp120 and gp140 has not previously been studied.
The breadth of the anti-HIV immune response is likely to be important in controlling HIV and has been studied extensively for NAb and CTL-based immune responses. Much work has been undertaken to generate ideas about how to induce bNAbs [33] and attempts have been made to induce broad CTL responses [34] to achieve protection against HIV [35] . To identify immune factors associated with control of HIV infection, we studied the breadth and strength of Env-specific ADCC responses from 11 HIV 'controllers' and compared these responses with those from 11 HIV 'progressors'.
Materials and methods

Study participants
The clinical characteristics of the 22 HIV-1 infected individuals are summarized in Table 1 . The HIV controller group included two elite controllers, one PTC, five viremic controllers and three LTSPs. Within the HIV controller group, three LTSP individuals had commenced cART (at a mean of 15.1 years after infection) having a CD4 þ cell count of more than 400 cells/ml and viral load of less than 5000 copies/ml 7 years after initial infection. In the HIV progressor group, we included four individuals who had commenced cART within 8 months of HIV diagnosis. HIV progressors all had a plasma viral load off cART of more than 10 000 copies/ml. All individuals were recruited and consented to donate sodium heparin anticoagulated plasma samples for use in ADCC assays; healthy HIVnegative volunteers provided the donor cells. Research was conducted under the auspices of the Alfred Human Health Research and Ethics Committee.
HIV-1 antigens
The 18 HIV-1 gp120 and gp140 proteins utilized in the ADCC assays are summarized in Table 2 , representing four major HIV subtypes (A, B, C and E; subtype E Env is from CRF01_AE). The reagents were obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH and Immune Technology Corp, New York as indicated in Table 2 .
To determine whether various glycosylation patterns affected ADCC recognition of Env, different glycosylated forms of HIV-1 AD8 gp140 were prepared. The wild-type glycosylated form of HIV-1 AD8 gp140 bearing both complex and mannose N-linked glycans was expressed and purified in HEK 293T cells as previously described ('Complex and Mannose') [36] . Wild-type glycosylated gp140 was treated with Endoglycosidase-H (NEB, Massachusetts, USA) overnight at 378C under nondenaturing conditions to cleave mannose N-linked glycans, but not processed complex oligosaccharides from glycoproteins, resulting in gp140 with only complex carbohydrates ('Complex-only'). The 'Mannose-only' gp140 was produced in HEK 293S GnT1 -cells that cannot synthesize complex N-glycans [37] . The mannose-only gp140 produced in GnT1 -cells was treated with Endoglycosidase-H overnight at 378C under nondenaturing conditions to cleave all N-linked glycans from the gp140 ('Nonglycosylated').
Antibody-dependent cellular cytotoxicity mediated natural killer cell activation assay
The intracellular cytokine staining (ICS)-based ADCCmediated NK cell activation assay was used to analyse cytokine production and degranulation of ADCCactivated NK cells as described previously [38, 39] . In brief, 150 ml of HIV-negative healthy donor whole blood (from a single healthy donor) and 50 ml HIV-positive plasma was incubated at 378C with different HIV-1 Env (1 mg/ml) for 5 h in the presence of Brefeldin A (final conc. 10 mg/ml; Sigma-Aldrich, St. Louis, Missouri, USA), Monensin (final conc. 10 mg/ml; BD Biosciences, San Jose, California, USA) and APC-H7-conjugated anti-CD107a antibody (clone H4A3; Biolegend, San Diego, California, USA). Following incubation, cells were surface stained with Per-CP-conjugated anti-CD3 (clone SK7; Biolegend) and PE-Cy7-conjugated anti-CD56 (clone HCD56; Biolegend) antibodies. Next, whole blood was treated with lysing solution (BD Biosciences) to remove red blood cells and the remaining white blood cells were treated with permeabilization solution (BD Biosciences) and stained with APCconjugated anti-IFN-g antibody (clone B27; Biolegend). Flow cytometry data were collected using a FACS Canto II Flow cytometer (BD Biosciences) and were analysed using Flow Jo version 10.0.6 software. NK cells were identified as CD3 -CD56 þ and responses were considered positive if the response [%NK cells expressing interferongamma (IFN-g) and/or CD107a] was more than three times that of unstimulated NK cells incubated with HIVpositive plasma. ADCC responses were measured as %NK cells expressing IFN-g and CD107a and the magnitude of ADCC responses was categorized as low (<2%), medium (2-8%) and high (>8% NK cell activation). The experiments using different glycosylated forms of HIV-1 gp140 were supplemented with 5 ng/ml interleukin (IL)-15 (R&D systems, Minneapolis, Minnesota, USA) for the 5 h incubation to enhance the NK cell activation as previously published [40] . This allowed better comparisons of responses in NK cell activation.
Antibody-dependent cellular cytotoxicity mediated killing using the rapid fluorometric ADCC assay The rapid fluorometric ADCC (RFADCC) assay was used as previously described [41, 42] . Briefly, 10 6 CEM.NKr-CCR5 cells in 100 ml of RF10 medium (RPMI; Life Technologies, Carlsbad, California, USA, 10% foetal calf serum, 1% penicillin-streptomycin, 2% glutamine) were coated separately with 3 mg of purified HIV-1 gp140 subtype A, B, C and E for 1 h at room temperature. Uncoated CEM.NKr-CCR5 cells were treated identically in the absence of gp140 protein.
Coated and uncoated CEM.NKr-CCR5 cells were initially labelled with PKH26 (Sigma-Aldrich) and CFSE (Sigma-Aldrich). Around 2 Â 10 4 PKH26 and CFSE and labelled CEM.NKr-CCR5 target cells were incubated with human plasma (1 : 100 final dilution) for 30 min at 378C followed by addition of 2 Â 10 5 PBMCs (total volume of 100 ml) to achieve a target:effector cell ratio of 1 : 10. Cells were incubated for 4 h at 378C and then stained with Per-CP-conjugated anti-CD3 (clone SK7; Biolegend) and APC-H7-conjugated anti-CD14 (clone MfP9; BD Biosciences) antibodies. Flow cytometry data were collected using a FACS LSR II Flow cytometer (BD Biosciences). The data analysis was performed using Flow Jo version 10.0.6 software and gating strategy as previously described [41] . For all gp140 responses, the no antigen control (uncoated target cells) responses were subtracted.
Statistical analyses
Statistical analyses were performed using SPSS version 18 software (IBM, Armonk, New York, USA). MannWhitney U-tests or Wilcoxon Signed Ranks tests were used to compare groups as indicated in the results section and figure legends. Median and interquartile range (IQR) was used to describe the data for Mann-Whitney U-tests and Wilcoxon Signed Ranks tests. A P value of 0.05 was considered to indicate a significant difference. Fisher exact tests were performed using the http://www.vassar stats.net website.
Results
Broad antibody-dependent cellular cytotoxicity mediated natural killer cell activation to different HIV-1 Env subtypes Given the high sequence diversity of HIV, for an HIV vaccine to be globally effective, immune responses need to be broad and able to recognize multiple subtypes of HIV [25] . Twenty-two individuals primarily infected with HIV-1 subtype B (Table 1) were recruited to study the ability of ADCC antibodies in the plasma of these individuals to recognize diverse range of HIV-1 gp120 and gp140 proteins from subtype A, B, C and E (Table 2) . Eleven individuals were designated as HIV controllers, having had HIV infection for 5-19 years without cART, maintaining a CD4 þ T-cell count of more than 400 cells/ ml and a low HIV viral load of less than 5000 copies/ml as per the definitions of the controller groups (Table 1) . Eleven individuals were HIV progressors, having a high viral load prior to cART of more than 10 000 copies/ml (Table 1) . We first used an ADCC assay that studied ADCC-mediated NK cell activation; Fig. 1a shows the gating strategy for this assay. We detected broad ADCCmediated NK cell activation to different subtypes of both HIV-1 gp120 and gp140. Figure 1b shows an example of ADCC antibodies in the plasma from an HIV controller able to recognize HIV-1 Env subtype B as well as subtype E gp120 and gp140 proteins. Figure 1c shows an example of ADCC responses in the plasma from one HIV controller (individual #6 in Table 1 ) in comparison to one HIV progressor (individual #12 in Table 1 ) against all Env (10 gp120 and 8 gp140 proteins) across four HIV subtypes. The HIV controller plasma demonstrated ADCC-mediated NK cell activation against all proteins tested, whereas the HIV progressor plasma recognized a much smaller subset of Env proteins with much lower magnitude of NK cell activation.
We noted that ADCC responses to the same concentrations of gp120 proteins were typically higher than to gp140 tested in our initial evaluations (seen in Fig. 1b, c) . To formally evaluate this further, we tested ADCC responses in plasma from all 22 individuals against HIV-1 Env of four different subtypes for which we had both gp120 and gp140 proteins. We found that the magnitude of ADCC was significantly higher to HIV-1 gp120 than to gp140 across all individuals (median 2.1% NK cell activation, IQR 5.1% to HIV-1 gp120 vs. median 1.4% NK cell activation, IQR 2.8% to HIV-1 gp140; Wilcoxon-Signed Ranks test P < 0.001; Fig. 1d ).
HIV controllers have broader antibodydependent cellular cytotoxicity mediated natural killer cell activation than HIV progressors HIV controllers are a model to study partial control of HIV [14, 17, 19, 43, 44] . When comparing plasma from 11 HIV controllers with 11 HIV progressors, we detected broader and more potent ADCC responses in HIV controllers ( Fig. 2a and b) . HIV controllers had significantly broader ADCC (10/11 individuals had cross-reactivity to one or more HIV-1 gp120 subtype) than HIV progressors (4/11; Fisher exact two-tailed P ¼ 0.02). On average, HIV controllers displayed medium or high ADCC response (>2% NK cell activation) to a median of eight different HIV-1 gp120 proteins (IQR 4) compared with one for HIV progressors (IQR 5; Mann-Whitney U-test P ¼ 0.001). Figure 2a (left-hand side heat map) shows that 11 of 11 HIV controllers generated more than 2% Env-specific ADCC responses to gp120 compared with five of 11 HIV progressors (Fisher exact two-tailed P ¼ 0.01). The magnitude of HIV-1 gp120-specific ADCC responses of HIV controllers (median 4.3% NK cell activation, IQR 5.7%) was significantly higher than HIV progressors (median 0.6% NK cell activation, IQR 1.4%; MannWhitney U-test P < 0.001, Fig. 2a left-hand side heat map). A medium or high ADCC (>2% NK cell activation) to more than two subtypes of the gp120 subtypes was detected in nine of 11 HIV controllers compared with two of 11 HIV progressors (Fisher exact two-tailed P ¼ 0.008). A similar pattern of ADCC responses between individual groups was noted to HIV-1 gp140 Envs (Mann-Whitney U-test P < 0.001, Fig. 2a right-hand side heat map).
In our cohort, three of the 11 HIV controllers and four of the 11 HIV progressors had commenced cART. The comparison of ADCC responses between cART-naive controllers (median 4.3% NK cell activation, IQR 6.2%) and cART-naive progressors (median 0.4% NK cell activation, IQR 0.8%) to HIV-1 gp120 was striking (Mann-Whitney U-test P < 0.001, Fig. 2a left-hand side heat map). This is in the setting of cART-naive controllers having significantly lower viral load (median ¼ 329 cocopies/ml, IQR 1055) compared with cART-naive progressors (median 49900 copies/ml, IQR ¼ 58100; Mann-Whitney U-test P ¼ 0.004, Table 1 ), although their CD4 þ cell count was similar (median CD4 þ cell count ¼ 687 cells/ml, IQR 519 in cART-naive controllers vs. median CD4 þ cell count ¼ 649 cells/ml, IQR 395 in cART-naive progressors; Mann-Whitney U-test P ¼ 0.281, Table 1 ).
Antibody-dependent cellular cytotoxicity mediated killing is higher in HIV controllers than in HIV progressors
To confirm the results above using the NK cell activation ADCC assay and to further assess killing of target cells by ADCC, we studied the ADCC-mediated killing using the RFADCC assay (Fig. 3a shows the gating strategy for this assay as previously described [41] ). We studied plasma from a randomly selected subset of seven HIV controllers and seven HIV progressors against HIV-1 gp140 subtype A, B, C and E. Overall, we found good reactivity to HIV-1 gp140 subtype B (ADCC-mediated killing range 20-45%) and E (range 3-41%), less reactivity to subtype A (range 3-15%) and minimal to subtype C (range 0-4%) in all the individuals (Fig. 3b) . This was in agreement with the findings of the NK cell activation ADCC assay wherein HIV-1 gp140 of subtype C overall elicited a weaker ADCC response than that of subtype B (median 1.35% NK cell activation, IQR 3.3% to subtype B #1 vs. 0.65% NK cell activation, IQR 1.3% to subtype C#1, Mann-Whitney U-test P ¼ 0.002, Fig. 2a right-hand side heat map).
Comparing HIV controllers with HIV progressors in the RFADCC assay, we found a significantly higher magnitude of %ADCC-mediated killing in HIV controllers than in HIV progressors to both HIV-1 gp140 subtype B (median 38% killing, IQR 7.5% in HIV controllers vs. 24% killing, IQR 8.4% in HIV progressors; Mann-Whitney U-test P ¼ 0.001) and the heterologous subtype E gp140 proteins (median 29% killing, IQR 8.5% in HIV controllers vs. 13.5% killing, IQR 8% in HIV progressors; Mann-Whitney U-test P ¼ 0.001, Fig. 3b ).
Higher antibody-dependent cellular cytotoxicity mediated natural killer cell activation to glycosylated HIV-1 gp140 than nonglycosylated form The potential of the glycans added during HIV Env biosynthesis to affect HIV-specific immune responses in vivo is debated. Glycosylation can result in both inhibition (e.g. by masking critical protein epitopes) and augmentation (e.g. glycan-dependent epitope) of an immune response, but the relative importance of glycosylation in ADCC recognition of Env is not clear [45, 46] . We therefore compared ADCC responses with HIV-1 AD8 gp140 with different glycosylation profiles purified from transfected 293T or 293S GnT1 -cells in a subset of 11 individuals with good ADCC responses. We found that the glycosylated form of HIV-1 gp140 triggered higher ADCC as opposed to the nonglycosylated form. Figure 4a (top) shows an example of the ADCCmediated NK cell activation to glycosylated and nonglycosylated gp140 in the ADCC-mediated NK cell activation assay using plasma from an HIV controller. ADCC-mediated NK cell IFN-g expression was significantly lower for the nonglycosylated gp140 (P ¼ 0.02; Wilcoxon Signed Ranks test; Fig. 4b lefthand side plots). Given the lower magnitude of ADCC responses to gp140 than gp120 as previously mentioned, we amplified the magnitude of NK cell activation using IL-15 supplementation, a technique we have previously employed [40] . This allowed better comparisons of differences in NK activation. Figure 4a responses, we observed an increase in median NK cell IFN-g expression from 12.6 to 21.1% and median CD107a degranulation from 2.9 to 4.5% to glycosylated gp140 (Fig. 4b) treatment. The IL-15 augmented ADCC responses of five individuals (median of triplicates) to HIV-1 gp140 with different glycan profiles show higher ADCC to HIV-1 gp140 with complex and/or mannose glycans than the nonglycosylated form (Fig. 4c) . Taken together, our findings suggested that ADCC Abs produced during natural HIV infection recognize epitopes with a glycan component. This may also be due to glycans stabilizing Env structure for better presentation of epitopes to ADCC Abs or forming part of epitope itself.
Discussion
People who naturally control HIV infection can assist in our understanding of the immune correlates of protection from disease progression. Although CTL and NAb responses are associated with control of HIV infection, vaccines based on these principles have failed to provide protection in human efficacy trials [2, 47] . The role of HIV-specific ADCC is gaining prominence following the posthoc analyses of the partially successful RV144 trial [6] [7] [8] Our results indicate that ADCC responses in HIV controllers commonly recognized most of the four major subtypes of HIV-1 spread across the globe. This contrasts with the limited development of bNAbs that develop in most HIV-infected people [48] . We found highest reactivity to subtype B and heterologous subtype E HIV-1 Envs, lower reactivity to subtype A Envs and only limited reactivity to subtype C Envs. This was consistent across both ADCC-mediated NK cell activation and ADCC-mediated killing assays. The robust cross-recognition of ADCC responses to B and E subtypes is interesting in the context of the partially successful RV144 trial, which used a bivalent B/E strategy and may point to an important common epitope shared across these subtypes. The modest recognition of subtypes A and C Envs in our primarily subtype B infected cohort suggests that, if ADCC-based vaccines are successful, a multivalent approach may be needed for a global HIV vaccine to cover all relevant subtypes effectively.
Glycosylation of HIV-1 Env is critical for folding of Env into functional form. Several bNAbs targeting Env epitopes with a glycan component have been reported [29] , but no research has been reported for ADCC Abs. Our novel findings suggest that HIV-1 Env ADCC responses commonly target glycan-dependent epitopes. A potential limitation of these studies is that our gp140 glycosylation variants were produced in 293-derived cells and there will be at least subtle differences in glycosylation patterns of gp140 present on the outside of infected lymphocytes [49] [50] [51] [52] . It is, however, difficult to generate purified glycosylation mutant gp140 proteins in infected lymphocytes and the striking reduction in ADCC recognition of de-glycosylated variants we observed strongly suggests that ADCC responses recognize a significant number of glycan-dependent epitopes. Further studies are needed to completely dissect the role of glycosylation and to identify conserved glycandependent epitopes.
In summary, broadly reactive ADCC responses in subtype B infected HIV controllers frequently target a range of HIV-1 subtype B and E Env and in some cases also subtype A and C Env. This indicates the potential utility of eliciting ADCC responses with novel HIV vaccines. Characterizing conserved ADCC epitopes should help in designing globally relevant ADCC-based HIV vaccines. 
